United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc (NYSE:PFE) has been trying to nudge its way into the weight-loss drug buzz with its own twice-daily version called danuglipron.

Pfizer Scraps Obesity Pill Study, Stock Hits 3-Year Lows

Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects.

Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides

Shares in Pfizer Inc (NYSE:PFE) dropped 6% after its highly touted weight loss pill danuglipron showed significant side effects, stopping people from using it. Pfizer will now focus on a once-daily formulation of the pill after the mid-stage study on a twice-daily version showed that while it had a significant effect on weight reduction, side effects forced many participants to stop taking it.

Pfizer shares knocked by fat drug trial setback

Investors' have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight loss drug makers Eli Lilly (shares up 60%) and Novo Nordisk (shares up 50%).

Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low

Eli Lilly

Novo Nordisk

Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.

Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes

'We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm,' Pfizer said.

Pfizer's Weight Loss Drug Won't Enter a Phase 3 Trial. The Stock Drops.

Pfizer Inc.'s stock PFE, +1.30% fell 4% premarket Friday, after the company said it's not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adults with obesity and type 2 diabetes after high rates of adverse events in the Phase 2b trial. The company said that study met its primary endpoint of statistically significant change in body weight compared with placebo.

Pfizer's stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates of side effects such as nausea and vomiting.

Pfizer drops plan to study twice-daily obesity pill in late-stage studies

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline. Twice-daily dosing of danuglipron showed statistically significant reductions from baseline in b.

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Attorney General Ken Paxton alleges Pfizer also attempted to silence critics of its vaccine.

Texas AG Sues Pfizer Over Covid Vaccine Effectiveness

Enterprise Products Partners

Verizon

When it comes to winning investment strategies, buying dividend stocks tends to rise to the top. It's likely because these are successful, profitable companies that have been battle-tested over time and still come out on top.

Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love

Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine.

Pfizer is sued by Texas over COVID-19 vaccine claims

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?

Moderna

Novavax

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

AbbVie

Johnson & Johnson

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

4 Large Drug Stocks to Watch as IBD Market Gains Traction

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its third annual TGaS Digital Marketing Competency Report assessing 160+ biopharma brands through the lens of digital marketing patient/caregiver experiences. The study evaluates the brands across five categories and more than 100 characteristics to understand each one's digital marketing presence and establish a brand digital competency ranking. Brands that topped the.

Pfizer's Nurtec Receives Top Ranking in 2023 TGaS Digital Marketing Competency Report

Pfizer's (NASDAQ: PFE) stock continued its 11-month decline in November after its third-quarter sales missed expectations amid waning demand for Covid products.

How to earn $500 a month from this stock?

Hasbro

Aptiv Holdings Ltd

Evercore

Lazard

Match Group

Newmont Mining

Block

Some of the stocks dumped as funds do tax-loss selling can be attractive buys.

Eight Beaten-Down Stocks Including Pfizer and Hasbro That Look Like Bargains

Pfizer Inc. (NYSE:PFE ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Dave Denton - CFO and EVP Conference Call Participants Umer Raffat - Evercore ISI Dave Denton Okay. Great. Umer Raffat Excellent.

Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Digital Realty Trust

Estee Lauder

Merck

Paramount Global

Stanley Black & Decker

Tyson Foods

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.

7 Companies Will Propel Profit More Than 100% Next Year: Analysts

Medtronic

The stock market is enjoying some holiday cheer. Amid signs that inflation is letting up and the Federal Reserve may finally put an end to its rate hikes, traders are piling into all sorts of investments right now.

3 Top-Rated Value Stocks That Analysts Are Loving Now

Mastercard

The second half of November saw announcements of annual dividend increases from nine companies, including an 11% increase from Nike. Merck's annual dividend boost will be deferred to December. Widely-held Broadcom and Mastercard will announce their annual dividend increases in December. I'm expecting 10%+ from both these companies. Sixteen other companies will announce annual increases before Christmas, including healthcare companies Stryker, Eli Lilly, and Bristol-Myers Squibb.

Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December

While Pfizer (NYSE: PFE) surged and became a household name during the COVID-19 pandemic due to the demand for its vaccines, the company has been on a decisive downward trajectory ever since.

ChatGPT predicts Pfizer stock price for start of 2024

Weight loss drugs have been at the heart of Eli Lilly and Novo Nordisk's market-beating performances this year. Pfizer is also developing a weight loss candidate that has been billed as a potential mega-blockbuster.

Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?

Apple

Ares Capital

American Express

Bank of America

Blackrock Inc

Crown Castle International

I will show you how you can build a dividend portfolio by allocating $100,000 among November's top 20 dividend companies as well as one ETF. I will conduct a deep risk analysis to demonstrate the reduced risk level of this portfolio and the elevated likelihood of it achieving attractive investment outcomes over the long term. This dividend portfolio provides you with a weighted average dividend yield [TTM] of 4.05% and a weighted average dividend growth rate [CAGR] of 10.58%, combining dividend income and dividend growth.

News for Pfizer Stock (PFE)